EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Polypharmacy in psychiatry and weight gain: longitudinal study of 832 patients hospitalized for depression or schizophrenia, along with data of 3180 students from Europe, the U.S., South America, and China

H H Stassen, S Bachmann, R Bridler, K Cattapan, E Seifritz

European Archives of Psychiatry and Clinical Neuroscience · 2025

DOI: 10.1007/s00406-024-01767-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Archives of Psychiatry and Clinical Neuroscience, 2025. Verfasst von H H Stassen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Psychotherapy and Psychosomatics, Institute for Response-Genetics, Psychiatric University Hospital, 8032, Zurich, Switzerla…. Hauptthemen laut MEDLINE: Weight Gain, Polypharmacy, Schizophrenia, Major Depressive Disorder. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Seventh Framework Programme, University of Zurich.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidemiologic data indicate that overweight and obesity are on the rise worldwide. Psychiatric patients are particularly vulnerable in this respect as they have an increased prevalence of overweight and obesity, and often experience rapid, highly undesirable weight gain under psychotropic drug treatment. Current treatment strategies in psychiatry are oriented towards polypharmacy, so that the information on drug-induced weight gain from earlier monotherapy studies is of very limited validity. We have analyzed the longitudinal data of 832 inpatients with ICD-10 diagnoses of either F2 (schizophrenia; n = 282) or F3 (major depression; n = 550) with the goal of ranking treatment regimens in terms of weight gain, side effects, and response to treatment. The patient data were complemented by the data of 3180 students aged 18–22 years, with which we aimed to identify factors that enable the early detection and prevention of obesity and mental health problems. After 3 weeks of treatment, 47.7% of F2 patients and 54.9% of F3 patients showed a weight gain of 2 kg and more. Major predictive factors were “starting weight” (r = 0.115), “concurrent medications” (r = 0.176), and “increased appetite”(r = 0.275). Between 11 and 30% of the observed variance in weight gain could be explained by these factors, complemented by sex and age. The comparison between monotherapy (n = 409) and polypharmacy (n = 399) revealed significant drawbacks for polypharmacy: higher weight gain ( p = 0.0005), more severe side effects ( p = 0.0011), and lower response rates (F2: p = 0.0008); F3: p = 0.0101). The data of 3180 students made it clear that overweight and obesity often begin early in life among those affected, and are interconnected with personality traits, while increasing the risk of developing psychosomatic disturbances, mental health problems, or somatic illnesses. Although the available data did not readily lead to a comprehensive, clinically applicable model of unwanted weight gain, our results have nevertheless demonstrated that there are ways to successfully counteract such weight gain at early stages of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Weight GainPolypharmacySchizophreniaMajor Depressive DisorderHumansMaleFemaleAdolescentYoung AdultLongitudinal StudiesEuropeAdultChinaStudentsHospitalizationAntipsychotic Agents

Stichwörter der Autor:innen

AntidepressantsAntipsychoticsConcurrent medicationsEfficacyMonotherapyPolypharmacySide effect profilesWeight gain

Substanzen

Antipsychotic Agents

Autor:innen und Institutionen

  • Department of Psychiatry, Psychotherapy and Psychosomatics, Institute for Response-Genetics, Psychiatric University Hospital, 8032, Zurich, Switzerland. k454910@bli.uzh.ch.
  • Department of Psychiatry, Psychotherapy, and Psychosomatics, University of Halle, 06112, Halle, Germany.
  • Germany and Clienia AG, Psychiatric Hospital, 9573, Littenheid, Switzerland.
  • Department of Psychiatry, Geneva University Hospitals, 1226, Thônex, Switzerland.
  • Sanatorium Kilchberg, 8802, Kilchberg, Switzerland.
  • University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland.

Förderung

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Seventh Framework Programme
  • University of Zurich

Zitieren

APA

Stassen, H. H., Bachmann, S., Bridler, R., Cattapan, K., & Seifritz, E. (2025). Polypharmacy in psychiatry and weight gain: longitudinal study of 832 patients hospitalized for depression or schizophrenia, along with data of 3180 students from Europe, the U.S., South America, and China. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-024-01767-2

Vancouver

Stassen HH, Bachmann S, Bridler R, Cattapan K, Seifritz E. Polypharmacy in psychiatry and weight gain: longitudinal study of 832 patients hospitalized for depression or schizophrenia, along with data of 3180 students from Europe, the U.S., South America, and China. European Archives of Psychiatry and Clinical Neuroscience. 2025. doi:10.1007/s00406-024-01767-2

BibTeX
@article{Stassen2025,
  author = {Stassen, H H and Bachmann, S and Bridler, R and Cattapan, K and Seifritz, E},
  title = {Polypharmacy in psychiatry and weight gain: longitudinal study of 832 patients hospitalized for depression or schizophrenia, along with data of 3180 students from Europe, the U.S., South America, and China},
  journal = {European Archives of Psychiatry and Clinical Neuroscience},
  year = {2025},
  doi = {10.1007/s00406-024-01767-2}
}
Kostenlos starten →